Article: New Report: More than 160 medicines in development for mental illness

PhRMA released a report and a list of new therapies under development for mental illnesses.  The article notes:

• 54 for depression, which affects 8.4% of adults and 17% of adolescents aged 12 to 17 in the U.S.
• 35 for schizophrenia, which affects less than 1% of U.S. adults.
• 35 for anxiety disorders. More than a third of adults in the U.S. report experiencing anxiety during their lifetime.
• 33 for substance use disorders. Over 40 million Americans ages 12 and older—or 14.5% of the U.S. population—reported having a substance use disorder in 2020.
• 13 for bipolar disorder which affects about 2.8% of adults and 2.9% of adolescents in the U.S.
• 8 for attention-deficit/hyperactivity disorder (ADHD) which is one the most common childhood disorders with a lifetime prevalence of 11.0% in children ages four to 17 and 8.7% in adolescents ages 13 to 18. ADHD also affects 4.4% of adults in the U.S.
  

The report can be accessed here and the list of new therapies here.